← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCStandard DatabasestalePhase 2
Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)
Roche / Genentech·Mantle-cell Lymphoma
1 trials
Overview
Program
Polatuzumab, bendamustin und rituximab
Overview
Company
Roche / Genentech
Overview
Modality
ADC
Overview
Target
Mantle-cell Lymphoma
Overview
Indication
Mantle-cell Lymphoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
[What is established in the treatment of diffuse large B-cell lymphoma?].. Diffuse large B‑cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with a median age at diagnosis of 71 years, predominantly affecting older adults. Risk factors include immunodeficiency, autoimmune disorders, viral infections, and certain environmental exposures, although most cases …
Clinical
Safety signal
[What is established in the treatment of diffuse large B-cell lymphoma?].. Diffuse large B‑cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with a median age at diagnosis of 71 years, predominantly affecting older adults. Risk factors include immunodeficiency, autoimmune disorders, viral infections, and certain environmental exposures, although most cases …
Clinical
Program phase
PHASE_2